MX2022008065A - 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos. - Google Patents

25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos.

Info

Publication number
MX2022008065A
MX2022008065A MX2022008065A MX2022008065A MX2022008065A MX 2022008065 A MX2022008065 A MX 2022008065A MX 2022008065 A MX2022008065 A MX 2022008065A MX 2022008065 A MX2022008065 A MX 2022008065A MX 2022008065 A MX2022008065 A MX 2022008065A
Authority
MX
Mexico
Prior art keywords
crystalline
methods
cholest
hydroxy
liquid crystalline
Prior art date
Application number
MX2022008065A
Other languages
English (en)
Inventor
Shawn Johnstone
Stephan D Parent
Jie Li
Robert Wenslow
Travis Lee Houston
Andrew Miksztal
Michael Holtz-Mulholland
Flavio Lopez
Howard Sard
Mario Gonzalez
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of MX2022008065A publication Critical patent/MX2022008065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

En el presente documento se describen formas cristalinas y líquidas cristalinas de 25HC3S de sodio. La descripción incluye las Formas I, II, III, V, IX, XI y XIII de 25HC3S de sodio y combinaciones de los mismas. Las formas farmacéuticas de las formas, o combinaciones de las mismas, y métodos para tratar o prevenir enfermedades tales como hipercolesterolemia, hipertrigliceridemia y afecciones relacionadas con la acumulación de grasa y la inflamación (por ejemplo, enfermedad del hígado graso no alcohólico (EHGNA), esteatohepatitis no alcohólica (EHNA), hepatitis alcohólica, lesión renal aguda (IRA), psoriasis y aterosclerosis) se describen adicionalmente en el presente documento. También se proporcionan métodos para preparar 25HC3S.
MX2022008065A 2019-12-27 2020-12-23 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos. MX2022008065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962954279P 2019-12-27 2019-12-27
PCT/US2020/066947 WO2021133976A1 (en) 2019-12-27 2020-12-23 Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same

Publications (1)

Publication Number Publication Date
MX2022008065A true MX2022008065A (es) 2022-07-27

Family

ID=76575692

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008065A MX2022008065A (es) 2019-12-27 2020-12-23 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos.

Country Status (13)

Country Link
US (1) US20230056273A1 (es)
EP (1) EP4081028A4 (es)
JP (1) JP2023508985A (es)
KR (1) KR20220119459A (es)
CN (1) CN115103591A (es)
AU (1) AU2020415462A1 (es)
BR (1) BR112022011358A2 (es)
CA (1) CA3165765A1 (es)
CL (1) CL2022001742A1 (es)
IL (1) IL294286A (es)
MX (1) MX2022008065A (es)
TW (1) TW202135829A (es)
WO (1) WO2021133976A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021133976A1 (en) * 2019-12-27 2021-07-01 Durect Corporation Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
KR20240040457A (ko) 2022-09-21 2024-03-28 현대모비스 주식회사 에어백 장치 및 그 전개 제어방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5218700B2 (es) * 1973-02-16 1977-05-24
US4046760A (en) * 1976-07-01 1977-09-06 Merck & Co., Inc. Process for preparing 1-α-hydroxy cholesterol derivatives
GB1592170A (en) * 1977-01-07 1981-07-01 Hoffmann La Roche 1a-hydroxycholecalciferol-25-hydroxy esters and their use in radioimmunoassay
OA06115A (fr) * 1978-03-11 1981-06-30 Etat Du Procédé de réparation du dihydroxy-24,25 cholestérol .
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US20090143279A1 (en) * 2007-06-15 2009-06-04 Vamsi Krishna Mootha Methods and compositions for treating metabolic disorders
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
PL3639828T3 (pl) * 2013-12-24 2022-05-02 Virginia Commonwealth University Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby
WO2021133976A1 (en) * 2019-12-27 2021-07-01 Durect Corporation Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same

Also Published As

Publication number Publication date
BR112022011358A2 (pt) 2022-08-23
KR20220119459A (ko) 2022-08-29
EP4081028A4 (en) 2024-03-06
US20230056273A1 (en) 2023-02-23
CN115103591A (zh) 2022-09-23
WO2021133976A1 (en) 2021-07-01
CA3165765A1 (en) 2021-07-01
TW202135829A (zh) 2021-10-01
AU2020415462A1 (en) 2022-06-23
EP4081028A1 (en) 2022-11-02
IL294286A (en) 2022-08-01
CL2022001742A1 (es) 2023-03-24
JP2023508985A (ja) 2023-03-06

Similar Documents

Publication Publication Date Title
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
MX2022008065A (es) 25-hidroxi-colest-5-en-3-sulfato de sodio cristalino y cristalino liquido y metodos para preparar los mismos.
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
EA202092001A1 (ru) Соединения для лечения болезни гентингтона
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
NZ724740A (en) Treatment of nafld and nash
SV2017005512A (es) Composiciones farmacéuticas para terapia combinada
PH12019502288A1 (en) Ask1 inhibitor compounds and uses thereof
MX2020008244A (es) Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella.
BR112015020600A2 (pt) composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição
EA202091219A1 (ru) Культивирование плаценты с целью выделения экзосом
BRPI0819690B8 (pt) uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas
SG10201806854XA (en) Compositions comprising 15-ohepa and methods of using the same
MX2018008528A (es) Composiciones y métodos para la administración intravenosa de 2-bromo-1-(3,3 dinitroazetidin-1-il)etanona.
IL284345A (en) Preparations and methods for the treatment of non-alcoholic fatty liver diseases
EA201890859A1 (ru) Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот
MX2018013221A (es) Compuestos de pirazol disustituidos para el tratamiento de enfermedades.
NZ754372A (en) Heterocyclic modulators of lipid synthesis
EP3781158A4 (en) COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC FAT LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS
MX2021002902A (es) Composicion farmaceutica para prevenir o tratar la enfermedad del higado graso no alcoholico, que contiene ligando gpr119 como principio activo.
EA201790315A1 (ru) Модуляторы x-рецепторов печени
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
CR20230126A (es) CONSTRUCCIONES DE iARN Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DE MARC1
WO2021041561A3 (en) Treating non-alcoholic fatty liver disease and inflammatory steatohepatitis with slc25a1 inhibitors